Author:
Zhong Jiaojiao,Le Wenjing,Li Xuechun,Su Xiaohong
Abstract
Abstract
Background
With the widespread use of antibiotics, antimicrobial resistance in Neisseria gonorrhoeae is worsening. The objective of this study was to evaluate the efficacy changes of seven antibiotics in the treatment of N. gonorrhoeae by using Monte Carlo simulation combined with pharmacokinetics/pharmacodynamics/ (PK/PD).
Methods
The minimum inhibitory concentration (MIC) of antibiotics against clinical isolates from 2013 to 2020 in Nanjing, China, was determined by agar dilution method. The probability of target attainment (PTA) was estimated at each MIC value and the cumulative fraction of response (CFR) was calculated to evaluate the efficacy of these regimens.
Results
All dosage regimens of seven antibiotics achieved PTAs ≥ 90% for MIC ≤ 0.06 µg/ml. But when the MIC was increased to 1 µg/ml, PTAs at each MIC value exceeded 90% only for ceftriaxone 1,000 mg and 2,000 mg, zoliflodacin 2,000 mg and 3,000 mg. Among them, the CFR values of each dosing regimen against N. gonorrhoeae only for ceftriaxone, cefixime and zoliflodacin were ≥ 90% in Nanjing from 2013 to 2020.
Conclusions
Cephalosporins are still the first-line drugs in the treatment of gonorrhea. However, the elevated MIC values of cephalosporins can lead to decline in clinical efficacy of the conventional dose regimens, and increasing the dose of ceftriaxone to 1,000 mg-2,000 mg may improve the efficacy. In addition, zoliflodacin is possible to be a potential therapeutic agent in the future.
Funder
Chinese Academy of Medical Sciences Initiative for Innovative Medicine
U.S. National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. World Health Organization. 2022.Multi-drug resistant gonorrhoea. https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea. Accessed 1 May. 2022.
2. Lin EY, Adamson PC, Klausner JD. Epidemiology, treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: current strategies and future directions. Drugs. 2021;81(10):1153–69.
3. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually transmitted Infections Treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
4. Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;2020. 956462420949126.
5. Guidelines for diagnosis. And treatment of Syphilis, gonorrhea and genital Chlamydia trachomatis Infection. Chin J Dermatology. 2020;53(3):168–79.